Novel insulin sensitizers: Pharmacogenomic aspects

Pharmacogenomics

Volumn 3, Issue 1, 2002, Pages 99-116

  Otto, Carsten ^a   Lebrke, Michael ^a   Göke, Burkhard ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Diabetes mellitus; Glucose transporter; Insulin signaling; Mutation; Peroxisome proliferator response element; Peroxisome proliferator activated receptor; Polymorphism; Protein kinase C; Retinoid X receptor

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; CELL NUCLEUS RECEPTOR; CIGLITAZONE; DNA; ENGLITAZONE; FATTY ACID; GLITAZONE DERIVATIVE; GLUCOSE; ICOSAPENTAENOIC ACID; INSULIN; LIGAND; LINOLENIC ACID; LIPOPROTEIN; NETOGLITAZONE; NUCLEAR PROTEIN; ORAL ANTIDIABETIC AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PROSTAGLANDIN SYNTHASE; REGLITAZAR; RETINOIC ACID RECEPTOR; RETINOID X RECEPTOR; ROSIGLITAZONE; STEROID RECEPTOR; SULFONYLUREA; THYROID HORMONE RECEPTOR; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITAMIN D RECEPTOR;

ANTIINFLAMMATORY ACTIVITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; GENE TARGETING; GENETIC CODE; GENETIC VARIABILITY; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HUMAN; HYPERINSULINEMIA; INSULIN SENSITIVITY; LIVER TOXICITY; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; RECEPTOR BINDING; RECEPTOR UPREGULATION; REVIEW; SENSITIZATION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

DIABETES MELLITUS, TYPE 2; DNA-BINDING PROTEINS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; POLYMORPHISM, GENETIC; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SIGNAL TRANSDUCTION; THIAZOLES; THIAZOLIDINEDIONES; TISSUE DISTRIBUTION; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; VARIATION (GENETICS);

EID: 0036203360     PISSN: 14622416     EISSN: None     Source Type: Journal    
DOI: 10.1517/14622416.3.1.99     Document Type: Review

References (183)

1. Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects
2. Effect of new oral antidiabetic agent CS-045 on glucose tolerance and insulin secretion in patients with NIDDM
3. Thiazolidinediones in the treatment of insulin resistance and Type II diabetes
4. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone
5. Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients
6. Nonhypoglycemic effects of thiazolidinediones
7. Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors
8. Isolation of the human peroxisome proliferator activated receptor gamma cDNA: Expression in hematopoietic cells and chromosomal mapping
9. Structural organization of mouse peroxisome proliferator-activated receptor gamma (mPPAR gamma) gene: Alternative promoter use and different splicing yield two mPPAR gamma isoforms
10. The peroxisome proliferator activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiation
11. A structural role for hormone in the thyroid hormone receptor
12. Crystal structure of the RAR-gamma ligand-binding domain bound to all- trans retinoic acid
13. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma
14. Differential activation of peroxisome proliferator-activated receptor- gamma by troglitazone and rosiglitazone
15. The mouse peroxisome proliferator activated receptor recognizes a response element in the 5¢ flanking sequence of the rat acyl CoA oxidase gene
16. The RXR heterodimers and orphan receptors
17. Polarity and specific sequence requirements of peroxisome proliferator-activated receptor (PPAR)/retinoid X receptor heterodimer binding to DNA. A functional analysis of the malic enzyme gene PPAR response element
18. Differential expression of peroxisome proliferator-activated receptors (PPARs): Tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat
19. Expression of the peroxisome proliferator-activated receptor (PPAR) in the mouse colonic mucosa
20. Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway
21. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators
22. Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages
23. Skeletal peroxisomal proliferator-activated receptor-γ expression in obesity and non-insulin dependent diabetes mellitus
24. Control of glycaemia
25. Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: No alteration in adipose tissue of obese and NIDDM patients
26. Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein
27. Distribution of peroxisome proliferator-activated receptors (PPARs) in human skeletal muscle and adipose tissue: Relation to insulin action
28. Regulation of PPAR gamma gene expression by nutrition and obesity in rodents
29. Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids
30. TNF alpha-mediated inhibition and reversal of adipocyte differentiation is accompanied by suppressed expression of PPARgamma without effects on Pref-1 expression
31. Depot-specific differences in adipose tissue gene expression in lean and obese subjects
32. Oxidized alkyl phospholipids are specific, high affinity peroxisome proliferator-activated receptor gamma ligands and agonists
33. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma
34. Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs
35. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma)
36. A new thiazolidinedione, NC-2100, which is a weak PPAR-gamma activator, exhibits potent antidiabetic effects and induces uncoupling protein 1 in white adipose tissue of KKAy obese mice
37. A potent antidiabetic thiazolidinedione with unique peroxisome proliferator-activated receptor gamma-activating properties
38. Novel peroxisome proliferator-activated receptor (PPAR) gamma and PPARdelta ligands produce distinct biological effects
39. Peroxisome proliferator-activated receptor mediates cross-talk with thyroid hormone receptor by competition for retinoid X receptor. Possible role of a leucine zipper-like heptad repeat
40. The directly repeated RG(G/T)TCA motifs of the rat and mouse cellular retinol-binding protein II genes are promiscuous binding sites for RAR, RXR, HNF-4, and ARP-1 homo-and heterodimers
41. Transactivation of the peroxisome proliferator-activated receptor is differentially modulated by hepatocyte nuclear factor-4
42. Signaling cross-talk between peroxisome proliferator-activated receptor/retinoid X receptor and estrogen receptor through estrogen response elements
43. Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARgamma
44. Regulation of peroxisome proliferator-activated receptor gamma activity by mitogen-activated protein kinase
45. Interdomain communication regulating ligand binding by PPAR-γ
46. Troglitazone inhibits angiotensin II-induced extracellular signal-regulated kinase 1/2 nuclear translocation and activation in vascular smooth muscle cells
47. Troglitazone enhances glucose uptake and inhibits mitogen-activated protein kinase in human aortic smooth muscle cells
48. Role of CBP/P300 in nuclear receptor signalling
49. A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors
50. Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase
51. A complex containing N-CoR, mSin3 and histone deacetylase mediates transcriptional repression
52. Stoichiometric and steric principles governing repression by nuclear hormone receptors
53. A transcriptional corepressor that interacts with nuclear hormone receptors
54. Cloning and identification of mouse steroid receptor coactivator-1 (mSRC-1), as a coactivator of peroxisome proliferator-activated receptor gamma
55. The antidiabetic agent thiazolidinedione stimulates the interaction between PPAR gamma and CBP
56. Nuclear receptor coactivators
57. Nuclear receptor coactivators and corepressors
58. A signature motif in transcriptional co-activators mediates binding to nuclear receptors
59. Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene
60. Ligand type-specific interactions of peroxisome proliferator-activated receptor gamma with transcriptional coactivators
61. A peroxisome proliferator-activated receptor gamma ligand inhibits adipocyte differentiation
62. A synthetic triterpenoid, 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO), is a ligand for the peroxisome proliferator-activated receptor gamma
63. The effects of thiazolidinediones on vascular smooth muscle cell activation by angiotensin II
64. Facilitative glucose transporters
65. Effects of troglitazone on cellular differentiation, insulin signaling, and glucose metabolism in cultured human skeletal muscle cells
66. Troglitazone regulation of glucose metabolism in human skeletal muscle cultures from obese Type II diabetic subjects
67. Troglitazone effects on gene expression in human skeletal muscle of Type II diabetes involve up-regulation of peroxisome proliferator- activated receptor-gamma
68. Troglitazone enhances differentiation, basal glucose uptake, and Glut1 protein levels in 3T3-L1 adipocytes
69. Troglitazone induces GLUT4 translocation in L6 myotubes
70. Troglitazone enhances differentiation, basal glucose uptake, and Glut1 protein levels in 3T3-L1 adipocytes
71. Protein-protein interaction in insulin signaling and the molecular mechanisms of insulin resistance
72. Expression of a constitutively active Akt Ser/Thr kinase in 3T3-L1 adipocytes stimulates glucose uptake and glucose transporter 4 translocation
73. Physiological role of Akt in insulin-stimulated translocation of GLUT4 in transfected rat adipose cells
74. Requirement of atypical protein kinase clambda for insulin stimulation of glucose uptake but not for Akt activation in 3T3-L1 adipocytes
75. The antidiabetic agent pioglitazone increases expression of glucose transporters in 3T3-F442A cells by increasing messenger ribonucleic acid transcript stability
76. Pioglitazone improves insulin signaling defects in skeletal muscle from Wistar fatty (fa/fa) rats
77. An antidiabetic thiazolidinedione potentiates insulin stimulation of glycogen synthase in rat adipose tissues
78. Insulin-stimulated tyrosine phosphorylation of caveolin is specific for the differentiated adipocyte phenotype in 3T3-L1 cells
79. Thiazolidinediones and insulin resistance: Peroxisome proliferator activated receptor gamma activation stimulates expression of the CAP gene
80. Acute effect of troglitazone on glucose metabolism in the absence or presence of insulin in perfused rat hindlimb
81. Acute effects of troglitazone on in vivo insulin action in normal rats
82. In L6 skeletal muscle cells, glucose induces cytosolic translocation of protein kinase C-alpha and trans-activates the insulin receptor kinase
83. Protein kinase C directly phosphorylates the insulin receptor in vitro and reduces its protein-tyrosine kinase activity
84. Chronic activation of protein kinase C in soleus muscles and other tissues of insulin-resistant Type II diabetic Goto-Kakizaki (GK), obese/aged, and obese/Zucker rats. A mechanism for inhibiting glycogen synthesis
85. Mechanisms of insulin resistance and new pharmacological approaches to metabolism and diabetic complications
86. Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C
87. Distinct effects of saturated fatty acids on protein kinase C subspecies
88. Insulin translocates PKC-epsilon and phorbol esters induce and persistently translocate PKC-beta 2 in BC3H-1 myocytes
89. Insulin administration in vivo increases 1,2-diacylglycerol in rat skeletal muscle
90. Insulin increases the synthesis of phospholipid and diacylglycerol and protein kinase C activity in rat hepatocytes
91. Effects of insulin on diacylglycerol-protein kinase C signaling in rat diaphragm and soleus muscles and relationship to glucose transport
92. Insulin increases distinct species of 1,2-diacylglycerol in isolated perfused rat heart
93. DAG accumulation from saturated fatty acids desensitizes insulin stimulation of glucose uptake in muscle cells
94. Phorbol esters modulate insulin receptor phosphorylation and insulin action in cultured hepatoma cells
95. Glucose-induced translocation of protein kinase C isoforms in rat-1 fibroblasts is paralleled by inhibition of the insulin receptor tyrosine kinase
96. Protein kinase C activity is acutely regulated by plasma glucose concentration in human monocytes in vivo
97. Mechanisms of action of troglitazone in the prevention of high glucose-induced migration and proliferation of cultured coronary smooth muscle cells
98. Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin sensitizing action in diabetic rats
99. Pioglitazone attenuates the inhibitory effect of phorbol ester on epidermal growth factor receptor autophosphorylation and tyrosine kinase activity
100. Reversal of chronic alterations of skeletal muscle protein kinase C from fat-fed rats by BRL-49653
101. Protein kinase C-zeta phosphorylates insulin receptor substrate-1 and impairs its ability to activate phosphatidylinositol 3-kinase in response to insulin
102. Thiazolidinedione treatment enhances insulin effects on protein kinase C-zeta/lambda activation and glucose transport in adipocytes of nondiabetic and Goto-Kakizaki Type II diabetic rats
103. Protein kinase C-zeta phosphorylates insulin receptor substrate-1 and impairs its ability to activate phosphatidylinositol 3-kinase in response to insulin
104. Regulation of the insulin signalling pathway by cellular protein-tyrosine phosphatases
105. High glucose-induced abnormal epidermal growth factor signaling
106. The antidiabetic agent pioglitazone increases expression of glucose transporters in 3T3-F442A cells by increasing messenger ribonucleic acid transcript stability
107. Transcriptional control of adipogenesis
108. PPAR-gamma: Adipogenic regulator and thiazolidinedione receptor
109. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor
110. Regulating adipogenesis
111. Control of adipocyte differentiation
112. Regulated expression of three C/EBP isoforms during adipose conversion of 3T3-L1 cells
113. Conditional ectopic expression of C/EBP beta in NIH-3T3 cells induces PPAR gamma and stimulates adipogenesis
114. Cross-regulation of C/EBP alpha and PPAR gamma controls the transcriptional pathway of adipogenesis and insulin sensitivity
115. Reconstitution of insulin-sensitive glucose transport in fibroblasts requires expression of both PPARgamma and C/EBPalpha
116. A role for C/EBPbeta in regulating peroxisome proliferator-activated receptor gamma activity during adipogenesis in 3T3-L1 preadipocytes
117. PPAR gamma is required for placental, cardiac, and adipose tissue development
118. PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance
119. PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro
120. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats
121. Thiazolidinediones and fatty acids convert myogenic cells into adipose-like cells
122. Trans-differentiation of myoblasts to adipoblasts: Triggering effects of fatty acids and thiazolidinediones
123. Peroxisome proliferator-activated receptor-gamma activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells
124. Post-transcriptional control of adipocyte differentiation through activation of phosphoinositide 3-kinase
125. Myogenic signaling of phosphatidylinositol 3-kinase requires the serine-threonine kinase Akt/protein kinase B
126. Transcriptional activation by peroxisome proliferator-activated receptor gamma is inhibited by phosphorylation at a consensus mitogen-activated protein kinase site
127. Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARgamma
128. The effects of thiazolidinediones on vascular smooth muscle cell activation by angiotensin II
129. Regulation of lipoprotein metabolism by thiazolidinediones occurs through a distinct but complementary mechanism relative to fibrates
130. Coordinate regulation of the expression of the fatty acid transporter protein and acyl-CoA synthetase genes by PPARalpha and PPARgamma activators
131. Treatment of insulin resistance with peroxisome proliferator-activated receptor γ agonists
132. Troglitazone action is independent of adipose tissue
133. Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones
134. The role of skeletal muscle Peroxisome Proliferator-Activated Receptor gamma in insulin sensitivity - A study with muscle-specific PPARgamma knockout mice
135. Adipogenesis and obesity: Rounding out the big picture
136. The hormone resistin links obesity to diabetes
137. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity
138. Glucose transport deficiency in diabetic animals is corrected by treatment with the oral antihyperglycemic agent pioglitazone
139. Regulation of glucose transport in cultured muscle cells by novel hypoglycemic agents
140. Potentiation of insulin stimulation of phosphatidylinositol 3-kinase by thiazolidinedione-derived antidiabetic agents in chinese hamster ovary cells expressing human insulin receptors and L6 myotubules
141. Thiazolidinediones: A new class of antidiabetic drugs
142. Treatment of insulin-resistant mice with the oral antidiabetic agent pioglitazone: Evaluation of liver GLUT2 and phosphoenolpyruvate carboxykinase expression
143. Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats
144. Acute non insulin like stimulation of rat muscle glucose metabolism by troglitazone in vitro
145. Troglitazone inhibits fatty acid oxidation and esterification, and gluconeogenesis in isolated hepatocytes from starved rats
146. Effects of a thiazolidinedione compound on body fat and fat distribution of patients with Type 2 diabetes
147. The peroxisome proliferator-activated receptor-α is a negative regulator of macrophage activation
148. PPARγ agonists inhibit production of monocyte inflammatory cytokines
149. BRL 49653 blocks the lipolytic actions of tumor necrosis factor-alpha (TNF-α): A potential new insulin-sensitizing mechanism for thiazolidinediones
150. A novel therapy for colitis utilizing PPAR-γ ligands to inhibit the epithelial inflammatory response
151. Troglitazone prevents insulin dependent diabetes in the non-obese diabetic mouse
152. Differential effect of the antidiabetic thiazolidinediones troglitazone and pioglitazone on human platelet aggregation mechanism
153. Troglitazone and related compounds. Therapeutic potential beyond diabetes
154. Differentiation and reversal of malignant changes in colon cancer through PPARγ
155. Activators of the nuclear receptor PPARγ enhance colon polyp formation
156. Min/1 mice
157. Effects of ligand activation of peroxisome proliferator-activated receptor γ in human prostate cancer
158. Ligands for peroxisome proliferator-activated receptor gamma inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells
159. Involvement of p21, p27, and p18 in troglitazone-induced cell cycle arrest in human hepatoma cell lines
160. Regulation of TRAIL-induced apoptosis by transcription factors
161. wafl/cipl
162. Troglitazone, an insulin sensitizer, increases forearm blood flow in humans
163. Troglitazone upregulates nitric oxyde synthesis in vascular smooth muscle cells
164. Thiazolidinediones down-regulate plasminogen activator inhibitor Type 1 expression in human vascular endothelial cells: A possible role for PPARgamma in endothelial function
165. Combination treatment with troglitazone, an insulin action enhancer, and pravastatin, an inhibitor of HMG-CoA reductase, shows a synergistic effect on atherosclerosis in WHHL rabbits
166. Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia
167. Potent inhibitory effect of troglitazone on carotid arterial wall thickness in Type 2 diabetes
168. Thiazolidinediones inhibit the production of monocyte chemoattractant protein 1 in cytokine-treated human vascular endothelial cells
169. Troglitazone inhibits formation of early atherosclerosis lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice
170. PPARγ promotes monocyte/macrophage differentiation and uptake of oxidized LDL
171. A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis
172. PPAR-a and PPAR-g activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway
173. Macrophages in human atheroma contain PPARgamma: Differentiation dependent peroxisomal proliferator- activated receptor gamma (PPAR-gamma) in mononuclear phagocytes in vitro
174. Dominant negative mutations in the human PPARγ associated with severe insulin resistance, diabetes mellitus and hypertension
175. A dominant-negative peroxisome proliferator-activated receptor γ (PPARγ) mutant is a constitutive repressor and inhibits PPARγ-mediated adipogenesis
176. 12Ala substitution in PPAR-gamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity
177. 12Ala polymorphism in the peroxisome proliferator-activated receptor-γ2 gene is associated with increased antilipolytic insulin sensitivity
178. PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance
179. 12Ala polymorphism is associated with decreased risk of Type 2 diabetes
180. 12Ala polymorphism of the PPARγ2 gene on long-term weight change in Finnish non-diabetic subjects
181. 972Arg)
182. Interactions between variants in the β3-adrenergic receptor and peroxisome proliferator-activated receptor-γ2 genes and obesity
183. Obesity associated with a mutation in a genetic regulator of adipocyte differentiation